DiagnaMed Announces Closing of LIFE Offering
DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) has successfully closed its private placement offering, raising $397,510 through the issuance of 13,250,333 units at $0.03 per unit. Each unit includes one common share and one purchase warrant, allowing holders to acquire an additional share at $0.05 within 24 months.
The company paid $29,760.80 in finders' fees and issued 992,027 finder warrants. The net proceeds will fund research, development, and commercialization of their hydrogen production and monitor technology and BRAIN AGE® Brain Health AI Platform, along with general corporate purposes.
Chairman and CEO Fabio Chianelli participated in the offering, subscribing for 850,000 units ($25,500). This related party transaction is exempt from formal valuation and minority shareholder approval requirements as it represents less than 25% of the company's market capitalization.
DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) ha concluso con successo la sua offerta di collocamento privato, raccogliendo $397,510 attraverso l'emissione di 13,250,333 unità a $0.03 per unità. Ogni unità comprende una azione comune e un warrant di acquisto, che consente ai titolari di acquisire un'azione aggiuntiva a $0.05 entro 24 mesi.
L'azienda ha pagato $29,760.80 in commissioni per i collocatori e ha emesso 992,027 warrant per i collocatori. I proventi netti finanzieranno la ricerca, lo sviluppo e la commercializzazione della loro tecnologia di produzione di idrogeno e monitoraggio e della piattaforma BRAIN AGE® Brain Health AI, insieme a scopi aziendali generali.
Il presidente e CEO Fabio Chianelli ha partecipato all'offerta, sottoscrivendo 850,000 unità ($25,500). Questa transazione con parti correlate è esente da valutazione formale e requisiti di approvazione degli azionisti di minoranza, in quanto rappresenta meno del 25% della capitalizzazione di mercato dell'azienda.
DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) ha cerrado con éxito su oferta de colocación privada, recaudando $397,510 a través de la emisión de 13,250,333 unidades a $0.03 por unidad. Cada unidad incluye una acción común y una opción de compra, que permite a los titulares adquirir una acción adicional a $0.05 dentro de 24 meses.
La empresa pagó $29,760.80 en comisiones a los colocadores y emitió 992,027 opciones de compra para los colocadores. Los ingresos netos financiarán la investigación, el desarrollo y la comercialización de su tecnología de producción de hidrógeno y monitoreo, así como de la plataforma BRAIN AGE® Brain Health AI, junto con fines corporativos generales.
El presidente y CEO Fabio Chianelli participó en la oferta, suscribiendo 850,000 unidades ($25,500). Esta transacción con partes relacionadas está exenta de la valoración formal y de los requisitos de aprobación de los accionistas minoritarios, ya que representa menos del 25% de la capitalización de mercado de la empresa.
DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF)는 성공적으로 사모펀드 공모를 마감하고 $397,510을 모금하였습니다. 이는 13,250,333 유닛을 유닛당 $0.03에 발행한 것입니다. 각 유닛은 하나의 보통주와 하나의 구매 워런트를 포함하며, 이는 보유자가 24개월 이내에 $0.05에 추가 주식을 취득할 수 있도록 합니다.
회사는 $29,760.80의 중개 수수료를 지급하고 992,027개의 중개인 워런트를 발행했습니다. 순수익은 수소 생산 및 모니터링 기술과 BRAIN AGE® 뇌 건강 AI 플랫폼의 연구, 개발 및 상용화를 위한 자금으로 사용되며, 일반 기업 목적에도 사용됩니다.
회장 겸 CEO인 파비오 키아넬리는 850,000 유닛($25,500)을 구독하며 공모에 참여했습니다. 이 관련자 거래는 회사의 시장 가치의 25% 미만을 차지하므로 공식 평가 및 소수 주주 승인 요구 사항에서 면제됩니다.
DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) a réussi à clore son offre de placement privé, levant $397,510 par l'émission de 13,250,333 unités à $0.03 par unité. Chaque unité comprend une action ordinaire et un bon de souscription, permettant aux détenteurs d'acquérir une action supplémentaire à $0.05 dans les 24 mois.
L'entreprise a payé $29,760.80 en frais de placement et a émis 992,027 bons de souscription. Les produits nets financeront la recherche, le développement et la commercialisation de leur technologie de production d'hydrogène et de surveillance ainsi que de la plateforme BRAIN AGE® Brain Health AI, ainsi que des fins d'entreprise générales.
Le président et PDG Fabio Chianelli a participé à l'offre, souscrivant 850,000 unités ($25,500). Cette transaction entre parties liées est exemptée de l'évaluation formelle et des exigences d'approbation des actionnaires minoritaires, car elle représente moins de 25 % de la capitalisation boursière de l'entreprise.
DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) hat erfolgreich ihr privates Platzierungsangebot abgeschlossen und $397,510 durch die Ausgabe von 13,250,333 Einheiten zu je $0.03 pro Einheit gesammelt. Jede Einheit umfasst eine Stammaktie und einen Kaufwarrant, der den Inhabern das Recht gibt, innerhalb von 24 Monaten eine zusätzliche Aktie zu einem Preis von $0.05 zu erwerben.
Das Unternehmen zahlte $29,760.80 an Vermittlungsgebühren und gab 992,027 Vermittlungswarrants aus. Der Nettoprozeß wird die Forschung, Entwicklung und Kommerzialisierung ihrer Wasserstoffproduktions- und Überwachungstechnologie sowie der BRAIN AGE® Brain Health AI-Plattform finanzieren, zusätzlich zu allgemeinen Unternehmenszwecken.
Der Vorsitzende und CEO Fabio Chianelli nahm an dem Angebot teil und zeichnete 850,000 Einheiten ($25,500). Diese Transaktion mit nahestehenden Personen ist von der formalen Bewertung und den Anforderungen zur Genehmigung durch Minderheitsaktionäre befreit, da sie weniger als 25% der Marktkapitalisierung des Unternehmens ausmacht.
- Successful capital raise of $397,510 strengthens company's financial position
- CEO shows confidence through personal investment of $25,500
- No resale restrictions on units under Canadian securities laws
- Significant dilution with issuance of 13,250,333 new units
- Low unit price of $0.03 indicates potential market weakness
- Additional dilution possible through warrant exercise at $0.05
Toronto, Ontario--(Newsfile Corp. - April 14, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed" or the "Company"), a leading provider of cutting-edge technology solutions for the hydrogen and life sciences industries, is pleased to announce that it has closed its previously announced private placement by issuing 13,250,333 units of the Company at an issue price of
Each unit consists of one common share in the capital of the company and one common share purchase warrant, with each warrant entitling the holder to acquire one additional common share for a period of 24 months from closing at an exercise price of
In connection with the closing of the offering, the Company paid finders' fees in the aggregate amount of
As disclosed in the offering document dated February 27, 2025, the Company intends to use the net proceeds from the offering for the research, development and commercialization of its hydrogen production and monitor technology and BRAIN AGE® Brain Health AI Platform, and for general corporate and working capital purposes. The offering document may be accessed under the Company's profile at SEDAR+ and on the Company's website.
All of the units were issued pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 - Prospectus Exemptions. As such, the units are not be subject to resale restrictions pursuant to applicable Canadian securities laws.
Fabio Chianelli, the Chairman and CEO of the Company, subscribed for 850,000 units, representing gross proceeds to the company of
About DiagnaMed
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) delivers innovative technology solutions for the cleantech and life sciences industries, with a focus on hydrogen production and AI-driven drug discovery and diagnostics. Visit DiagnaMed.com.
For more information, please contact:
Fabio Chianelli
Chairman and CEO
DiagnaMed Holdings Corp.
Tel: 416-800-2684
Email: info@diagnamed.com
Website: www.diagnamed.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement
Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-Looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as "will", "may", "expect", "could", "can", "estimate", "anticipate", "intend", "believe", "projected", "aims", and "continue" or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption "Risk Factors" in Company's management's discussion and analysis for the three-months ended December 31, 2024 ("MD&A"), dated February 24, 2025, which is available on the Company's profile at www.sedarplus.ca. Forward-Looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/248369
FAQ
How much did DiagnaMed (DGNMF) raise in their latest private placement?
What are the terms of DGNMF's warrant offering in April 2025?
How will DiagnaMed use the proceeds from their 2025 private placement?
What was CEO Fabio Chianelli's participation in DGNMF's private placement?
